Browse

Preventive effect of GV1001 on gemcitabine-induced pancreatic cancer cachexia
Gemcitabine에 의해 유도된 췌장암 악액질에 미치는 GV1001의 예방 효과

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
전재은
Advisor
이왕재
Major
의과대학 의학과
Issue Date
2016-08
Publisher
서울대학교 대학원
Keywords
cachexiagemcitabineGV1001muscle wasting
Description
학위논문 (석사)-- 서울대학교 대학원 : 의학과 해부학전공, 2016. 8. 이왕재.
Abstract
GV1001 derived from the human telomerase reverse transcriptase (hTERT) sequence is a peptide vaccine for the treatment of pancreatic cancer. The preclinical data clearly showed immunogenicity of GV1001 in patients with pancreatic cancer supported by the synergy of gemcitabine with cancer vaccines and the other positive immunomodulatory effects of gemcitabine. Even though it is reported that GV1001 may block weight loss of cancer patients and improve general condition after treatment of gemcitabine, but there are insufficient evidences so far. For this reason, we evaluate the preventive effect of GV1001 on gemcitabine-induced weigh loss in xenograft animal model. There was definite body weight loss and muscle weight loss of tumor-bearing mice by the treatment of gemcitabine. However, it was recovered by the treatment of gemcitabine with GV1001. In addition, we compared skeletal muscle proliferation and differentiation upon the treatment of gemcitabine with or without GV1001. When skeletal muscle cells were treated with gemcitabine only, the decrease of myogenesis was observed. The decrease is ameliorated by the co-treatment of GV1001. Upon investigation, the results demonstrate that GV1001 effectively prevents the loss of weight and the decrease in skeletal muscle proliferation and regeneration by gemcitabine.
Language
English
URI
https://hdl.handle.net/10371/132875
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Master's Degree_의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse